BSE filing, NSE: THYROCARE. Summary written from the filing by ALFA Finder's alert engine.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹493.40
- Market cap
- ₹7,853 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 44.5×Sector 51.1×
- Promoter holding
- 51.02%-9.90% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Board Meeting Date
Thyrocare Technologies intimated that its Board meeting is scheduled for 29 Oct 2026 to consider Q2/H1 FY27 results. No financial figures or decisions are reported in this prior intimation.
Thyrocare Technologies Other Announcement
Thyrocare Technologies filed its quarterly shareholding pattern for the period ended September 30, 2026, including a note regarding a prior promoter group amalgamation.
Thyrocare Technologies Annual General Meeting
Thyrocare Technologies initiated a postal ballot for two resolutions: purchasing property from its subsidiary, Nueclear Healthcare, and selling its investment in Nueclear Healthcare.
Thyrocare Technologies Annual General Meeting
Thyrocare seeks shareholder approval via postal ballot for the purchase of land and building and the divestment of its subsidiary, Nueclear Healthcare Limited.
- Value
- ₹162.0 Cr
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.
- Value
- ₹141.4 Cr
- Execution
- On or before November 30, 2026
Thyrocare Technologies Share Pledge
API Holdings, successor to promoter Docon, released a full pledge over 7.95 crore Thyrocare shares after NCD redemption. No Docon shares remain encumbered.
Other employee stock options announcements
All →Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.
Maxvolt Energy Industries Employee Stock Options
Maxvolt Energy granted 5,01,726 ESOPs to six employees under its MEIL ESOP 2025 scheme at exercise prices of ₹30 and ₹45. Options vest over four years, with exercise windows following vesting.
- Execution
- Vesting over 4 years from grant (25% at 2nd, 25% at 3rd, 50% at 4th anniversary); exercise over 3 years from each vesting date